Caranx Medical Receives FDA Clearance for AI-Powered Software Guiding Transcatheter Heart Valve Implantation
Caranx Medical announced FDA clearance for TAVIPILOT Soft, the world's first AI software for real-time intra-operative guidance of transcatheter aorti...
Breakthrough Clinical Results
Caranx Medical announced FDA clearance for TAVIPILOT Soft, the world's first AI software for real-time intra-operative guidance of transcatheter aortic valve implantation (TAVI). This software aims to improve the precision and safety of TAVI procedures, potentially increasing the number of patients who can benefit from this life-saving treatment. The clearance is a significant step towards Caranx's planned market introduction of TAVIPILOT Soft by the end of 2025. Caranx is also developing an autonomous robot for TAVI procedures, aiming to further democratize access to this technology.
Key Highlights
- FDA clearance for TAVIPILOT Soft, an AI-driven software for real-time guidance during TAVI procedures.
- Planned market introduction of TAVIPILOT Soft by the end of 2025.
- Potential to improve precision and patient outcomes in TAVI procedures.
- Development of an autonomous robot for TAVI procedures.
Incidence and Prevalence
Global Estimates of Aortic Valve Disease: Incidence and Prevalence
Based on the available PubMed information, specific global epidemiological data regarding the incidence and prevalence of aortic valve disease is not available. Current research literature accessible through PubMed does not provide comprehensive worldwide statistics on this cardiac condition.
Without reliable global estimates, it is not possible to present accurate figures on how commonly aortic valve disease occurs across different populations worldwide or how many new cases are diagnosed annually on a global scale.
Drug used in other indications
TAVIPILOT Soft Clinical Trials Information
After thorough analysis of the available data, there is no information available regarding clinical trials of TAVIPILOT Soft for indications beyond aortic valve disease. The data does not contain any details about:
- Additional clinical indications for TAVIPILOT Soft
- Intervention models or protocols for TAVIPILOT Soft trials
- Procedural techniques specific to TAVIPILOT Soft
- Implantation methodologies for this device
- Any trials investigating TAVIPILOT Soft for non-aortic valve indications
No information is available regarding the specific intervention protocols, procedural techniques, or implantation methodologies being utilized in any clinical trials of this device.
Company drugs in pipeline
Caranx Medical Pipeline Information
Based on a thorough review of the available information, there is no data regarding Caranx Medical's drug pipeline or the specific indications they are targeting with their investigational pharmaceutical compounds or biologics.
The search for information about Caranx Medical's development programs, including any preclinical or clinical stage candidates, did not yield any results. There is no information available about their therapeutic focus areas or the disease states for which they might be developing treatments.
Without additional information sources, it is not possible to provide details about Caranx Medical's pharmaceutical development activities or the medical conditions they aim to address with their potential drug candidates.
